Helsinn Healthcare SA
- Country
- 🇨🇭Switzerland
- Ownership
- Holding
- Established
- 1976-01-01
- Employees
- 501
- Market Cap
- -
- Website
- http://www.helsinn.com
Clinical Trials
122
Trial Phases
6 Phases
Drug Approvals
3
Drug Approvals
Netupitant and Palonosetron Hydrochloride Capsules
- Product Name
- 奥康泽
- Approval Number
- 国药准字HJ20190046
- Approval Date
- Apr 3, 2024
Palonosetron Hydrochloride Injection
- Product Name
- 盐酸帕洛诺司琼注射液
- Approval Number
- 国药准字HJ20210002
- Approval Date
- Jan 19, 2021
Netupitant and Palonosetron Hydrochloride Capsules
- Product Name
- 奥康泽
- Approval Number
- H20190046
- Approval Date
- Aug 2, 2019
Clinical Trials
Distribution across different clinical trial phases (78 trials with phase data)• Click on a phase to view related trials
Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC)
- Conditions
- Nausea and Vomiting Chemotherapy-InducedNausea Post Chemotherapy
- Interventions
- Drug: IV NEPA (fosnetupitant/palonosetron)
- First Posted Date
- 2025-04-01
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Helsinn Healthcare SA
- Target Recruit Count
- 95
- Registration Number
- NCT06904235
- Locations
- 🇬🇷
Aghia Sophia Children's Hospital, Pediatric Hematology/ Oncology Unit (POHemU), Athens, Greece
🇬🇷Mitera Hospital, Pediatric and Adolescent Oncology Department, Athens, Greece
🇬🇷"AHEPA" University General Hospital of Thessaloniki, 2nd Department of Pediatrics, Thessaloniki, Greece
A Clinical Trial to Assess Safety and Pharmacokinetics of Fosnetupitant 235 mg and Metabolites in Healthy Volunteers
- Conditions
- Healthy Volunteers
- Interventions
- Drug: Fosnetupitant 235 mg solutionDrug: Akynzeo solution
- First Posted Date
- 2025-02-21
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Helsinn Healthcare SA
- Target Recruit Count
- 50
- Registration Number
- NCT06840769
- Locations
- 🇨🇭
CROSS Research S.A., Arzo, Canton Ticino, Switzerland
Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations
- Conditions
- Advanced Solid TumorCNS TumorRecurrent WHO Grade II Glioma
- Interventions
- First Posted Date
- 2022-02-03
- Last Posted Date
- 2023-02-23
- Lead Sponsor
- Helsinn Healthcare SA
- Registration Number
- NCT05222165
- Locations
- 🇺🇸
Lucile Packard Children's Hospital at Stanford University Medical Center, Palo Alto, California, United States
🇺🇸Children's National Hospital - Brain Tumor Institute, Washington, District of Columbia, United States
🇺🇸Nicklaus Children's Hospital, Miami, Florida, United States
Oral Akynzeo® Vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk)
- Conditions
- Chemotherapy-induced Nausea and Vomiting
- Interventions
- Drug: Granisetron, 2 mg (oral) or 1 mg (IV) OR Palonosetron, 0.5 mg (oral), 0.25mg (IV) OR Ondansetron, 16 mg (oral) or 8 mg (IV) OR Dolasetron 100 mg (oral) OR Tropisetron 5 mg (oral or IV)Drug: NEPA (300mg netupitant/0.5mg palonosetron)Drug: Dexamethasone, 8 mg (oral) or equivalent IV dose
- First Posted Date
- 2021-03-26
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Helsinn Healthcare SA
- Target Recruit Count
- 414
- Registration Number
- NCT04817189
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, China
🇨🇳Shanghai Ninth People´s Hospital, Shanghai, China
🇨🇳Shanghai Obstetrics and Gynecology Hospital, Shanghai, China
A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Cachexia; CancerNon Small Cell Lung Cancer
- Interventions
- Drug: Placebo Oral Tablet
- First Posted Date
- 2018-11-15
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Helsinn Healthcare SA
- Target Recruit Count
- 318
- Registration Number
- NCT03743051
- Locations
- 🇺🇸
Chen, Tucson, Arizona, United States
🇺🇸CARTI Cancer Center, Little Rock, Arkansas, United States
🇺🇸The Oncology Insitute of Hope and Innovation, Riverside, California, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- Next